FindTrial
Sign In

Effect of 12 Weeks Practice of Anulom Vilom Pranayama as Adjunctive Therapy for Parkinson’s Disease

Effect of 12-Weeks Practice of Anulom Vilom Pranayama (Alternate Nostril Breathing) as Adjunctive Therapy on the Cardiac Autonomic Balance, Cognition, Psychological Status and Quality of Life in Individuals with Mild to Moderate Parkinson’s Disease: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/01/049251
Enrollment
86
Registered
2023-01-27
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: G20- Parkinsons disease

Interventions

Intervention1: Structured Anulom Vilom Pranayama will be given as adjunctive therapy to conventional therapy for patients with mild to moderate Parkinsons disease: The participants will be taken to AC

Sponsors

JIPMER
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with clinically diagnosed idiopathic Parkinsonism with Movement Disorder Society-Sponsored Revision of the Unified Parkinson Disease Rating Scale (MDS UPDRS) motor score less than 59 and Hoehn-Yahr staging score less than or equal to 2. On stable anti-parkinsonian therapy for the past 3 months. Both gender, age from 30 years to 65 years

Exclusion criteria

Exclusion criteria: Poorly controlled chronic cardiovascular or respiratory comorbidities. Advanced dementia or other unstable medical ill-nesses which may prevent the active participation of the study participants in the various study procedures. Patients with current active infections such as • tuberculosis or COVID-19 • Comorbid autoimmune diseases • Pre-existing endocrine disorders • Pre-existing hepatic and renal disease, connective tissue diseases, malignancies. Individuals who are already practicing some form of structured pranayama or yoga on a regular basis will also be excluded from the study

Design outcomes

Primary

MeasureTime frame
Cardiac sympathovagal balance - LF:HF ratioTimepoint: Change in LF:HF ratio from 0 week (baseline) to the end of 12 weeks—

Secondary

MeasureTime frame
a) Heart Rate Variability indices (Time domain and frequency domain indices) b) Autonomic function tests (heart rate response to deep breathing, blood pressure response to isometric handgrip). c) Cognition (P300, Auditory reaction time, Visual reaction time) d) Psychological status (DASS-21, PANAS-SF) e) Biochemical markers of cardiovascular risk and oxidative stress (s-Homocysteine and 8-hydroxy-2-deoxyguanosine) f) Quality of life (WHOQOL-BREF) Timepoint: Change in these study parameters from 0 week (baseline) to the end of 12 weeks—

Countries

India

Contacts

Public ContactMs Usha Dhanaradja

Jawaharlal Institute of Postgraduate Medical Education and Research

ushadanaraja@yahoo.co.in9994190989

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026